292 related articles for article (PubMed ID: 22714051)
1. Brain protection from stroke with intravenous TNFα decoy receptor-Trojan horse fusion protein.
Sumbria RK; Boado RJ; Pardridge WM
J Cereb Blood Flow Metab; 2012 Oct; 32(10):1933-8. PubMed ID: 22714051
[TBL] [Abstract][Full Text] [Related]
2. Neuroprotection with a brain-penetrating biologic tumor necrosis factor inhibitor.
Zhou QH; Sumbria R; Hui EK; Lu JZ; Boado RJ; Pardridge WM
J Pharmacol Exp Ther; 2011 Nov; 339(2):618-23. PubMed ID: 21831964
[TBL] [Abstract][Full Text] [Related]
3. Blood-Brain Barrier Penetrating Biologic TNF-α Inhibitor for Alzheimer's Disease.
Chang R; Knox J; Chang J; Derbedrossian A; Vasilevko V; Cribbs D; Boado RJ; Pardridge WM; Sumbria RK
Mol Pharm; 2017 Jul; 14(7):2340-2349. PubMed ID: 28514851
[TBL] [Abstract][Full Text] [Related]
4. Combination stroke therapy in the mouse with blood-brain barrier penetrating IgG-GDNF and IgG-TNF decoy receptor fusion proteins.
Sumbria RK; Boado RJ; Pardridge WM
Brain Res; 2013 Apr; 1507():91-6. PubMed ID: 23428543
[TBL] [Abstract][Full Text] [Related]
5. Brain-penetrating tumor necrosis factor decoy receptor in the mouse.
Zhou QH; Boado RJ; Hui EK; Lu JZ; Pardridge WM
Drug Metab Dispos; 2011 Jan; 39(1):71-6. PubMed ID: 20884844
[TBL] [Abstract][Full Text] [Related]
6. Neuroprotection in stroke in the mouse with intravenous erythropoietin-Trojan horse fusion protein.
Fu A; Hui EK; Lu JZ; Boado RJ; Pardridge WM
Brain Res; 2011 Jan; 1369():203-7. PubMed ID: 21047502
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics and brain uptake of an IgG-TNF decoy receptor fusion protein following intravenous, intraperitoneal, and subcutaneous administration in mice.
Sumbria RK; Zhou QH; Hui EK; Lu JZ; Boado RJ; Pardridge WM
Mol Pharm; 2013 Apr; 10(4):1425-31. PubMed ID: 23410508
[TBL] [Abstract][Full Text] [Related]
8. Selective targeting of a TNFR decoy receptor pharmaceutical to the primate brain as a receptor-specific IgG fusion protein.
Boado RJ; Hui EK; Lu JZ; Zhou QH; Pardridge WM
J Biotechnol; 2010 Mar; 146(1-2):84-91. PubMed ID: 20100527
[TBL] [Abstract][Full Text] [Related]
9. Biologic TNFα-inhibitors that cross the human blood-brain barrier.
Pardridge WM
Bioeng Bugs; 2010; 1(4):231-4. PubMed ID: 21327054
[TBL] [Abstract][Full Text] [Related]
10. Reduction in Brain Heparan Sulfate with Systemic Administration of an IgG Trojan Horse-Sulfamidase Fusion Protein in the Mucopolysaccharidosis Type IIIA Mouse.
Boado RJ; Lu JZ; Hui EK; Pardridge WM
Mol Pharm; 2018 Feb; 15(2):602-608. PubMed ID: 29251941
[TBL] [Abstract][Full Text] [Related]
11. Biologic TNF-α inhibitors reduce microgliosis, neuronal loss, and tau phosphorylation in a transgenic mouse model of tauopathy.
Ou W; Yang J; Simanauskaite J; Choi M; Castellanos DM; Chang R; Sun J; Jagadeesan N; Parfitt KD; Cribbs DH; Sumbria RK
J Neuroinflammation; 2021 Dec; 18(1):312. PubMed ID: 34972522
[TBL] [Abstract][Full Text] [Related]
12. Reengineering biopharmaceuticals for targeted delivery across the blood-brain barrier.
Pardridge WM; Boado RJ
Methods Enzymol; 2012; 503():269-92. PubMed ID: 22230573
[TBL] [Abstract][Full Text] [Related]
13. Tumor necrosis factor receptor-IgG fusion protein for targeted drug delivery across the human blood-brain barrier.
Hui EK; Boado RJ; Pardridge WM
Mol Pharm; 2009; 6(5):1536-43. PubMed ID: 19624167
[TBL] [Abstract][Full Text] [Related]
14. Monoclonal antibody-glial-derived neurotrophic factor fusion protein penetrates the blood-brain barrier in the mouse.
Zhou QH; Boado RJ; Lu JZ; Hui EK; Pardridge WM
Drug Metab Dispos; 2010 Apr; 38(4):566-72. PubMed ID: 20075191
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics and brain uptake of a genetically engineered bifunctional fusion antibody targeting the mouse transferrin receptor.
Boado RJ; Zhou QH; Lu JZ; Hui EK; Pardridge WM
Mol Pharm; 2010 Feb; 7(1):237-44. PubMed ID: 19921848
[TBL] [Abstract][Full Text] [Related]
16. Brain penetrating IgG-erythropoietin fusion protein is neuroprotective following intravenous treatment in Parkinson's disease in the mouse.
Zhou QH; Hui EK; Lu JZ; Boado RJ; Pardridge WM
Brain Res; 2011 Mar; 1382():315-20. PubMed ID: 21276430
[TBL] [Abstract][Full Text] [Related]
17. Reversal of lysosomal storage in brain of adult MPS-I mice with intravenous Trojan horse-iduronidase fusion protein.
Boado RJ; Hui EK; Lu JZ; Zhou QH; Pardridge WM
Mol Pharm; 2011 Aug; 8(4):1342-50. PubMed ID: 21667973
[TBL] [Abstract][Full Text] [Related]
18. Blood-brain barrier drug delivery of IgG fusion proteins with a transferrin receptor monoclonal antibody.
Pardridge WM
Expert Opin Drug Deliv; 2015 Feb; 12(2):207-22. PubMed ID: 25138991
[TBL] [Abstract][Full Text] [Related]
19. Re-engineering erythropoietin as an IgG fusion protein that penetrates the blood-brain barrier in the mouse.
Zhou QH; Boado RJ; Lu JZ; Hui EK; Pardridge WM
Mol Pharm; 2010 Dec; 7(6):2148-55. PubMed ID: 20860349
[TBL] [Abstract][Full Text] [Related]
20. Receptor-mediated abeta amyloid antibody targeting to Alzheimer's disease mouse brain.
Zhou QH; Fu A; Boado RJ; Hui EK; Lu JZ; Pardridge WM
Mol Pharm; 2011 Feb; 8(1):280-5. PubMed ID: 21141969
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
